GSA Capital Partners LLP Makes New $209,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

GSA Capital Partners LLP bought a new stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 6,512 shares of the company’s stock, valued at approximately $209,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Entropy Technologies LP purchased a new stake in SpringWorks Therapeutics in the 3rd quarter valued at approximately $320,000. Los Angeles Capital Management LLC grew its holdings in SpringWorks Therapeutics by 238.3% during the third quarter. Los Angeles Capital Management LLC now owns 47,212 shares of the company’s stock worth $1,513,000 after acquiring an additional 33,255 shares during the period. State of New Jersey Common Pension Fund D raised its position in SpringWorks Therapeutics by 1.9% in the third quarter. State of New Jersey Common Pension Fund D now owns 46,389 shares of the company’s stock worth $1,486,000 after acquiring an additional 871 shares in the last quarter. Assetmark Inc. lifted its holdings in SpringWorks Therapeutics by 13.7% in the third quarter. Assetmark Inc. now owns 46,020 shares of the company’s stock valued at $1,474,000 after acquiring an additional 5,546 shares during the period. Finally, Principal Financial Group Inc. boosted its position in shares of SpringWorks Therapeutics by 102.5% during the 3rd quarter. Principal Financial Group Inc. now owns 918,445 shares of the company’s stock worth $29,427,000 after purchasing an additional 464,903 shares in the last quarter.

SpringWorks Therapeutics Trading Up 7.5 %

Shares of NASDAQ SWTX opened at $39.02 on Monday. The stock has a fifty day moving average price of $32.60 and a 200 day moving average price of $36.74. The company has a market cap of $2.90 billion, a P/E ratio of -10.06 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 12-month low of $20.19 and a 12-month high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.03. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. The firm had revenue of $49.10 million during the quarter, compared to analysts’ expectations of $53.28 million. During the same quarter in the prior year, the business earned ($1.27) EPS. SpringWorks Therapeutics’s quarterly revenue was up 4810.0% compared to the same quarter last year. On average, sell-side analysts forecast that SpringWorks Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on SWTX. Wedbush reiterated an “outperform” rating and set a $77.00 target price on shares of SpringWorks Therapeutics in a research report on Monday, November 18th. Evercore ISI began coverage on SpringWorks Therapeutics in a report on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 price target for the company. JPMorgan Chase & Co. lifted their price target on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Finally, HC Wainwright lowered their price objective on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research note on Tuesday, November 12th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, SpringWorks Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $67.00.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.